Open AccessHepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study
Author(s) -
Danhong Yang,
Weiping Wang,
Qiang Zhang,
Hongying Pan,
Yicheng Huang,
Jiajie Zhang
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i17.2025
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , cirrhosis , hepatitis b virus , univariate analysis , lamivudine , hepatitis b , hepatitis c virus , cancer , immunology , multivariate analysis , virus
Antiviral therapy cannot completely block the progression of hepatitis B to hepatocellular carcinoma (HCC). Furthermore, there are few predictors of early HCC progression and limited strategies to prevent progression in patients with HBV-related cirrhosis who receive nucleos(t)ide analog (NA) therapy.